Intrathecal/Ommaya T-DXd for HER2‑expressing breast cancer with leptomeningeal or brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I/II open-label trial delivers T-DXd directly into the cerebrospinal fluid via intrathecal injection or an Ommaya reservoir alongside systemic therapy to measure safety and intracranial activity in patients with HER2‑expressing breast cancer and leptomeningeal or active brain metastases. Key endpoints include adverse events, intracranial response (using RANO-BM for measurable lesions), and pharmacokinetics of T-DXd and free DXd in CSF and blood. Eligible participants are adults with HER2‑expressing advanced or metastatic breast cancer who meet organ function and treatment-washout requirements. The trial aims to determine whether local intrathecal delivery can overcome blood–brain barrier limitations and inform development of targeted intracranial treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years, regardless of gender.
* HER2-expressing advanced or metastatic breast cancer
* Leptomeningeal metastasis
* Subjects with active brain metastases only must have at least one intracranially measurable lesion (RANO-BM criteria).
* Adequate organ and bone marrow function
* No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or surgery within 2 weeks prior to enrollment (or within 5 half-lives of prior therapy, whichever is shorter).
* All prior treatment-related toxicities must have resolved to ≤Grade 1

Exclusion Criteria:

* Diagnosis of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, other in situ carcinomas, or papillary thyroid carcinoma.
* Uncontrolled concurrent illnesses including, but not limited to: persistent or active infections, uncontrolled or clinically significant cardiovascular diseases, severe chronic gastrointestinal disorders with diarrhea, or psychiatric/social conditions that may compromise compliance with study requirements, significantly increase AE risks, or impair the subject's ability to provide written informed consent.
* History of (non-infectious) ILD/non-infectious pneumonitis requiring steroid therapy, current ILD/non-infectious pneumonitis, or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging during screening.
* Clinically significant pulmonary comorbidities
* Use of immunosuppressants or systemic corticosteroids (\>10 mg/day prednisone equivalent) for immunosuppression within 2 weeks prior to first dose (excluding intranasal/inhaled corticosteroids).
* Any active autoimmune disease or history of autoimmune disease with potential recurrence.
* Uncontrolled infections requiring IV antibiotics, antivirals, or antifungals.
* Active primary immunodeficiency, known HIV infection, active HBV (HBsAg+ with HBV DNA ≥500 IU/mL) or HCV infection. HCV antibody-positive subjects are eligible only if PCR confirms HCV RNA negativity.
* Radiographic evidence of tumor encasement/invasion of major blood vessels, or investigator-determined high risk of fatal hemorrhage due to probable vascular invasion during treatment.
* Pregnant/lactating women, or subjects of reproductive potential unwilling/unable to use effective contraception.
* Any other condition deemed by investigators to potentially affect trial conduct or outcome interpretation.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting
• Fudan University Shanghai Cancer Cancer
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jian Zhang, MD, PhD
• Email: syner2000@163.com
• Phone: +8664175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.